Compare DNN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | MLYS |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1998 | 2023 |
| Metric | DNN | MLYS |
|---|---|---|
| Price | $2.36 | $22.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $4.64 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 24.0M | 1.3M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $321.58 | N/A |
| Revenue Next Year | $38.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.20 | $21.46 |
| 52 Week High | $4.43 | $47.65 |
| Indicator | DNN | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 30.81 |
| Support Level | N/A | N/A |
| Resistance Level | $3.43 | $31.19 |
| Average True Range (ATR) | 0.12 | 1.30 |
| MACD | -0.02 | -0.61 |
| Stochastic Oscillator | 1.60 | 7.59 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.